INTRODUCTION
============

Affection of the respiratory muscles in or excluding the diaphragm has been occasionally reported as the cause of respiratory insufficiency in patients with mitochondrial myopathy (Table **[1](#T1){ref-type="table"}**) \[[@R1], [@R2]\]. Particularly, patients with progressive external ophthalmoplegia (PEO) seem to be prone to respiratory insufficiency \[[@R3]\]. Mitochondrial myopathy with affection of the respiratory muscles may not only be due to mtDNA but also due to nDNA mutations (Table **[1](#T1){ref-type="table"}**) \[[@R1], [@R2]\]. Respiratory insufficiency due to affection of the respiratory muscles has to be clearly delineated from respiratory insufficiency due to cerebral involvement in a mitochondrial disorder, like in Leigh- or Leigh-like syndrome or other mitochondrial encephalopathies \[[@R4]\]. Here we report a patient with long-standing PEO and ptosis, and a combined complex I+IV defect who developed successive, late-onset affection of the respiratory muscles.

CASE REPORT
===========

The patient is a 45y Caucasian male, height 182cm, weight 80kg, with a previous history of divergence of the ocular bulbs with double vision since age 6y, bilateral ptosis since age 23y, which was surgically corrected at age 30y, ophthalmoparesis since at least age 27y, a syncope at age 30y, and anterocollis since at least age 40y. At age 27y he had undergone muscle biopsy from the left deltoid muscle showing mild myopathic lesions with increased accumulation of intrafusal glycogen and lipid droplets. Electroneurography at age 27y revealed axonal polyneuropathy. 24h-ECG at age 30y disclosed an intermittent AV-block II and electroencephalography generalized poly-spike waves in the absence of seizures. Clinical neurologic investigation at age 40y revealed, in addition to the above mentioned abnormalities, bilateral proximal weakness of the upper limbs, a winging scapula bilaterally, and reduced tendon reflexes. Cerebrospinal fluid (CSF) investigations at age 40y revealed elevated protein (1008mg/l, n: 150-450mg/l) exclusively. Needle-(electromyography) EMG of the right anterior tibial muscle at age 40y showed neurogenic alterations. A Guillain-Barre-syndrome (GBS) was suspected and immunoglobulins administered with a beneficial effect. Transthoracic echocardiography at age 40y revealed mild myocardial thickening. At late age 40y mild weakness of the lower limbs (M5-/M4+) and an abnormal respiratory pattern were noted for the first time. Radioscopy of the lungs did not reveal abnormal mobility of the diaphragm. Lactate stress testing under 40W resulted in a lactate increase to 9.5mmol/l after 8 minutes. Upon supra-maximal stimulation of the phrenic nerve at age 41y no answer could be evoked and needle-EMG of the rectus abdominis muscle revealed abnormal spontaneous activity. Muscle biopsy from the right deltoid muscle at age 41y showed myopathic features, ragged-red fibers, regenerating fibers, increased number of lipid droplets, glycogen depositions, and some COX-negative fibers. Biochemical investigations of the muscle homogenate revealed a combined complex I+IV defect. The activity of the NADH-CoQ-oxidoreductase was 7.4 U/g NCP (n, 15.8-42.84 U/g NCP) and the activity of the cytochrome-c-oxidase 89 U/g NCP (n, 112-351 U/g NCP). Investigation for mtDNA deletions or insertions by long-range PCR was normal. Southern blot could not be carried out because of insufficient material. nDNA located genes responsible for mitochondrial myopathy were not tested. The family history was positive for diabetes (grandmother from the mother's side) and cardiac abnormalities (mother).

At age 45y he was admitted for acute respiratory dysfunction in the absence of recent pulmonary infection or embolism with hypercapnia but normal oxygenation due to weakness of the respiratory muscles (Table **[2](#T2){ref-type="table"}**). There was no indication for heart failure. Though he was awake with normal oxygenation, he required intubation and mechanical ventilation because of hypercapnia due to muscular respiratory insufficiency. Clinical neurologic examination revealed ptosis, ophthalmoparesis, weak head anteflexion and retroflexion (M5-), weakness of the upper limbs with distal predominance (M4 to M5-), proximal weakness of the lower limbs (M5-) absent tendon reflexes, generalized wasting, and stocking-type sensory disturbances. Blood tests revealed hyponatriemia (129mmol/l, n: 135-150mmol/l) and slight anemia (Table **[1](#T1){ref-type="table"}**). The diaphragm was moving normally. Cerebral CT was normal. Under controlled ventilation elevated CO~2~ decreased to near normal values within 3 days (Table **[2](#T2){ref-type="table"}**). On hospital day (hd) 3 he was extubated but respiratory insufficiency with hypercapnia recurred, why he required re-intubation and ventilatory support on hd5 (Table **[2](#T2){ref-type="table"}**). One day after re-intubation, tracheostomy was carried out. Blood gases normalized (Table **[2](#T2){ref-type="table"}**) and from hd8 ventilatory support could be discontinued during daytime. Since a GBS was additionally suspected upon the history and the elevated CSF-protein, immunoglobulins were given. Under this regimen respiratory function further improved and he was able to sit with support during daytime. Unsupported sitting was impossible due to affected truncal muscles.

DISCUSSION
==========

The patient was suffering from multisystem abnormalities affecting the extra-ocular muscles (PEO), the axial, limb, and respiratory muscles, the nerves, the heart, and subclinically the cerebrum. Initially, he was diagnosed with GBS and for this reason; he repeatedly received immunoglobulins with some benefits.

The cause of respiratory insufficiency in the presented patient is most likely attributable to progressive weakness of the respiratory muscles from the underlying mitochondrial myopathy. There was no indication for a triggering factor, no involvement of the brainstem, systolic dysfunction, or for lung disease. Typical morphological alterations indicative of a Leigh- or Leigh-like syndrome were absent on cerebral CT.

Combined complex I+IV deficiency has been rarely reported to manifest with involvement of the respiratory muscles \[[@R2], [@R5]-[@R7]\]. In the patient reported by Wolf *et al*. complex I+IV deficiency was due to the tRNA(Lys) mutation m. 8299G\>A \[[@R6]\]. In this patient, PEO was associated with recurrent respiratory insufficiency \[[@R6]\]. Another female child with a mitochondrial myopathy developed limb muscle weakness since age 3y. Muscle weakness deteriorated since age 28y. by the age 30y she developed muscular restrictive respiratory insufficiency \[[@R2]\]. At age 44y, the patient required artificial ventilation throughout night and four hours during daytime \[[@R2]\]. The same author reported another child with mitochondrial myopathy who developed progressive muscle weakness and wasting and respiratory insufficiency since age 31y \[[@R2]\]. Both patients carried a combined complex I+III+IV defect. Genetic tests revealed the mutation c.323C\>T in the TK2 gene in patient 1 and the c.8dup duplication in the TK2 gene in patient 2 \[[@R2]\]. Partial complex I+IV defect was detected in the muscle of a 13y patient who developed sudden-onset of respiratory insufficiency and quadru-spasticity, which was attributed to leukodystrophy \[[@R7]\].

Previously, several patients with PEO and affection of the respiratory muscles have been described (Table **[1](#T1){ref-type="table"}**) \[[@R3], [@R6], [@R8]-[@R19]\]. In a study of 23 patients with PEO, eight had reduced maximal expiratory mouth pressure \<65% \[[@R3]\]. In all eight patients, PEO was due to single mtDNA deletions \[[@R3]\]. In a patient with Kearns-Sayre syndrome (KSS), acute respiratory failure developed requiring invasive ventilatory support, which improved to a level where she required only non-invasive nocturnal BiPAP treatment \[[@R9]\]. In another patient with KSS, respiratory insufficiency with alveolar hypoventilation was attributed to diminished chemosensitivity to hypoxia and hypercapnia \[[@R13]\]. Reduced ventilatory drive due to depressed response to hypoxia or hypercapnia was also reported in three other patients with PEO \[[@R14]\]. In a study on the cause of death in 16 patients with PEO it turned out that two of them died from cardiopulmonary insufficiency without further specification of the respiratory contribution \[[@R12]\]. Two studies have shown that respiratory insufficiency can be the main cause of death in patients with PEO \[[@R12], [@R18]\]. In a study of 69 patients with PEO, two developed muscular respiratory failure and died from it \[[@R18]\]. In this study, the probability to develop extra-ocular manifestations was increased if onset of PEO was before the age 9y and was correlated with the amount of mtDNA deletion in blood lymphocytes \[[@R18]\]. Other patients with mitochondrial myopathy but without PEO or a combined complex I+IV defect who developed respiratory insufficiency from mitochondrial myopathy are listed in Table **[1](#T1){ref-type="table"}** \[[@R1], [@R20]-[@R25]\]. Patients with mitochondrial myopathy and PEO who developed respiratory insufficiency but unknown genetic or biochemical defect have also been reported \[[@R11], [@R14], [@R16], [@R17]\].

Treatment of respiratory insufficiency has been described elsewhere \[[@R3]\]. A major complication of decreased respiratory muscle weakness in mitochondrial myopathy is an increased risk of pneumonia \[[@R26]\]. If there is additional involvement of the laryngeal muscles, these patients are particularly prone to develop pneumonia since laryngeal muscle weakness may lead to aspiration of food and to insufficient glottis closure during coughing \[[@R12], [@R27], [@R28]\]. When insufficient glottis closure is combined with decreased inspiratory or expiratory strength, this may result in decreased generation of intra-thoracic pressure and thus impaired expectoration \[[@R3]\]. The mild beneficial effect of immunoglobulins might be due to a placebo effect, due to secondary immunological disease, or due to a chronic inflammatory demyelinating polyneuropathy (CIDP) as a second trouble. Arguments for a CIDP are the elevated CSF-protein, and the response to immunoglobulins. Arguments against CIDP, however, are that polyneuropathy was of the axonal type, that the immunoglobulin effect was only mild, and that mitochondrial myopathy has not been reported in association with CIDP. Immunoglobulins have not been reported to be generally beneficial in mitochondrial disorders.

CONCLUSION
==========

This case shows that a mitochondrial disorder due to a combined complex I+IV defect manifesting predominantly with PEO may progress to involvement of the limb-girdle, axial, and respiratory muscles, resulting in muscular respiratory insufficiency. In patients with a mitochondrial myopathy, neuropathy, and elevated CSF-protein, immunoglobulins may exhibit a beneficial effect.
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###### 

Mitochondrial myopathy due to mutations in mtDNA or nDNA located genes associated with affection of the respiratory muscles.

  References                       Gene        Mutation            Biochemical defect   PEO
  -------------------------------- ----------- ------------------- -------------------- -----
  Mar O'Callaghan 2012 \[[@R1]\]   tRNA(Val)   m.1643A\>G          CII+CIII             no
  Behin 2012 \[[@R2]\]             TK2         c.323C\>T           CI+CIII+CIV          no
  Behin 2012 \[[@R2]\]             TK2         c.8dup, c.268C\>T   CI+CIII+CIV          no
  Wolf 2012 \[[@R6]\]              tRNA(Lys)   m.8299G\>A          CI+CIV               yes
  Smits 2011 \[[@R3]\]^&^          nm          mtDNA deletion      nm                   yes
  Martin-Negrier 2011 \[[@R8]\]    TWINKLE     p.R374Q             nm                   yes
  Pronicki 2010 \[[@R20]\]\*       SCO2        p.E140K             CIV                  no
  Giordano 2009 \[[@R21]\]         POLG1       nm                  nm                   no
  Yuri 2008 \[[@R19]\]             nm          nm                  nm                   yes
  Sanaker 2007 \[[@R9]\]           nm          mtDNAdel            nm                   yes
  Aure 2007 \[[@R18]\]^%^          nm          mtDNAdel            nm                   yes
  Tong 2006 \[[@R22]\]             nm          nm                  VLCAD                no
  Saneto 2006 \[[@R23]\]           tRNA(Leu)   m.3243A\>G          CII overactivity     no
  Easley 2002 \[[@R24]\]           nm          nm                  PDG                  no
  Götz 2002 \[[@R10]\]             nm          nm                  nm                   yes
  Chotmongkol 2001 \[[@R11]\]      nm          nm                  nm                   yes
  Klopstock 1999 \[[@R12]\]        tRNA(Leu)   3243                nm                   yes
  Rabano 1998 \[[@R7]\]            nm          multiple mtDNAdel   partial CI+CIV       no
  Von Döbeln 1993 \[[@R5]\]        nm          nm                  CI+CIV               no
  Enter 1991 \[[@R25]\]            tRNA(Leu)   m.3243A\>G          nm                   no
  Osanai 1991 \[[@R13]\]           mtDNAdel    nm                  nm                   yes
  Barohn 1990 \[[@R14]\]^\#^       nm          nm                  nm                   yes
  Nozaki 1990 \[[@R15]\]           nm          nm                  CIV                  yes
  Desnuelle 1988 \[[@R16]\]        nm          nm                  nm                   yes
  Carroll 1976 \[[@R17]\]          nm          nm                  nm                   yes

Nm: not mentioned. VLCAC: very-long chain acyl-CoA dehydrogenase deficiency, PDG: pyruvate-dehydrogenase, \*: 13 homozygous cases, \#: 3 cases, &: 8 cases with PEO due to mtDNA deletion, %: 2 patients.

###### 

Blood gas analysis during hospitalisation.

  Parameter      RL              hd2    hd3    hd4    hd5    hd6    hd7    hd8    hd9    hd10
  -------------- --------------- ------ ------ ------ ------ ------ ------ ------ ------ ------
  pH             7.38-7.42       7.32   7.43   7.34   7.35   7.29   7.27   7.44   7.45   7.47
  pCO~2~         \-              74     50     54     62     77     70     53     52     44
  BE             \-              10.8   8.1    3.4    7.4    9.3    4.3    10.3   10.8   7.9
  sO~2~          \-              99     99     100    95     99     90     100    99     100
  Sodium         135-150mmol/l   142    142    141    nd     nd     142    145    142    nd
  Lactate        \-              0.7    0.6    0.6    0.5    nd     1.1    0.7    0.8    nd
  Erythrocytes   4.2-5.5 T/l     4.5    4.03   3.74   nd     nd     4.45   4.68   3.85   nd

RL: reference limits, hd: hospital day, BE: base excess, nd: not done.
